Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinxuening capsule for ischemic stroke with hyperhomocysteinemia
ChiCTR1800018371Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xinxuening and folic acid in ischemic stroke and hyperhomocysteinemia (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Homocysteine level, Adverse events and 1 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
xinxueningfolic acid
03
Conditions
ischemic strokehyperhomocysteinemia
Beyond the preview
Go deeper on ChiCTR1800018371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018371.